Viridian Therapeutics Inc
VRDN
Market Cap$1.2B
Close$
$1.05
92.8% downside
Current Fair Value
92.8% downsideOvervalued by 92.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.20 Billion |
|---|---|
| Enterprise Value | $1.11 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-3.98 |
| Beta | 0.46 |
| Outstanding Shares | 81,344,134 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -3.88 |
|---|---|
| PEG | -4.91 |
| Price to Sales | - |
| Price to Book Ratio | 2.09 |
| Enterprise Value to Revenue | 3663.34 |
| Enterprise Value to EBIT | -4.45 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Viridian Therapeutics Inc
27 employees
CEO: William Marshall Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R mono...